Evidence map›Paper›PMID 33201286›Full record

ArticleEuropean radiology2021

Prediction of mediastinal lymph node metastasis based on

Guotao Yin, Yingchao Song, Xiaofeng Li, Lei Zhu, Qian Su, Dong Dai, Wengui Xu

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. PretreatmentCancer imaging : the official publication of the International Cancer Imaging Society · 2023
    Article
  13. Predictive value ofEuropean journal of nuclear medicine and molecular imaging · 2023
    Article
  14. Review
  15. Article
  16. Review
  17. Predictive Value ofDiagnostics (Basel, Switzerland) · 2022
    Article
  18. Article
  19. Article
  20. Development and Validation of aFrontiers in oncology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Guotao Yin *Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi Distinct, Tianjin City, 300060, People's Republic of China.
Yingchao Song *School of Medical Imaging and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University, Tianjin, People's Republic of China.
Xiaofeng LiDepartment of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi Distinct, Tianjin City, 300060, People's Republic of China.
Lei ZhuDepartment of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi Distinct, Tianjin City, 300060, People's Republic of China.
Qian SuDepartment of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi Distinct, Tianjin City, 300060, People's Republic of China.
Dong DaiDepartment of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi Distinct, Tianjin City, 300060, People's Republic of China.
Wengui XuDepartment of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi Distinct, Tianjin City, 300060, People's Republic of China. wenguixy@yeah.net.
Tianjin Medical University Cancer Institute and Hospital · CNTianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe purpose of this study was to develop a classification method based on support vector machine (SVM) to improve the diagnostic performance of

methodTwo hundred nineteen lymph nodes (37 metastatic) from 71 patients were evaluated in this study. SVM models were developed with 7 LN features. The area under the curve (AUC) and accuracy of 9 models were compared to select the best model. The best SVM model was simplified on the basis of the feature weights and value distribution to further suit the clinical application.

resultsThe maximum, minimum, and mean accuracy of the best model was 91.89% (68/74, 95% CI 83.11~96.54%), 66.22% (49/74, 95% CI 54.85~75.98%), and 80.09% (59,266/74,000, 95% CI 70.27~89.19%), respectively, with an AUC of 0.94, 0.66, and 0.81, respectively. The best SVM model was finally simplified into a score rule: LNs with scores more than 3.0 were considered as malignant ones, whereas LNs with scores less than 1.5 tended to be benign ones. For the LNs with scores within a range of 1.5-3.0, metastasis was suspected.

conclusionAn SVM model based on KEY POINTS: • The SVM model based on

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsFluorodeoxyglucose F18HumansLymphatic MetastasisLymph NodesNeoplasm StagingPositron-Emission TomographyPositron Emission Tomography Computed TomographyRetrospective StudiesSupport Vector MachineFluorodeoxyglucose F18Fluorodeoxyglucose F18Lymphatic metastasisNon-small cell lung carcinomaPositron emission tomography/computed tomographySupport vector machine

Identifiers

PMID33201286
OpenAlexW3104315716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.